Kyverna Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-74.0M | — |
| FY2023 | — | $-13.1M | $34.6M |
| FY2024 | — | $266.6M | $96.6M |
| FY2025 | — | $232.3M | $124.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-74.0M | — |
| FY2023 | — | $-13.1M | $34.6M |
| FY2024 | — | $266.6M | $96.6M |
| FY2025 | — | $232.3M | $124.1M |